Martingale Asset Management L P Immunovant, Inc. Transaction History

Martingale Asset Management L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$15.27 - $19.72 $276,463 - $357,030	-18,105 Reduced 45.59%	21,605 $335,000
Q4 2022 Feb 13, 2023	SELL	$6.59 - $17.75 $200,520 - $540,097	-30,428 Reduced 43.38%	39,710 $704,000
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $290 - $471	74 Added 0.11%	70,138 $392,000
Q2 2022 Aug 11, 2022	BUY	$3.38 - $5.65 $43 - $73	13 Added 0.02%	70,064 $273,000
Q1 2022 May 12, 2022	BUY	$5.06 - $8.77 $41,492 - $71,914	8,200 Added 13.26%	70,051 $385,000
Q4 2021 Feb 11, 2022	BUY	$7.33 - $9.32 $21,257 - $27,028	2,900 Added 4.92%	61,851 $526,000
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $276,404 - $448,319	39,430 Added 201.99%	58,951 $512,000
Q2 2021 Aug 13, 2021	BUY	$9.4 - $16.85 $183,497 - $328,928	19,521 New	19,521 $206,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.